Barclays Maintains Overweight on Oruka Therapeutics, Raises Price Target to $160

Benzinga Newsdesk www.benzinga.com Positive 72.9%

Neg 0% Neu 0% Pos 72.9%

Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and raises the price target from $78 to $160.